Abstract: The present invention provides methods for identifying viral virulence factors and for identifying cellular polypeptides to which the viral polypeptides bind. The cellular polypeptide is useful as a therapeutic target or as a therapeutic agent for treating diseases and disorders, including immunological diseases or disorders.
Type:
Application
Filed:
September 14, 2012
Publication date:
May 23, 2013
Applicant:
Viral Logic Systems Technology Corp.
Inventors:
Steven Wiley, Craig A. Smith, Ajamete Kaykas
Abstract: The present invention provides methods for identifying viral virulence factors and for identifying cellular polypeptides to which the viral polypeptides bind. The cellular polypeptide is useful as a therapeutic target or as a therapeutic agent for treating diseases and disorders, including immunological diseases or disorders.
Type:
Grant
Filed:
March 22, 2007
Date of Patent:
October 23, 2012
Assignee:
Viral Logic Systems Technology Corp.
Inventors:
Steven Wiley, Craig A Smith, Ajamete Kaykas
Abstract: Provide herein are fusion polypeptides that comprise a CD47 extracellular domain or a variant thereof that is fused to a Fc polypeptide. The fusion polypeptides are useful for treating an immunological disease or disorder in a subject according to the methods described herein. The fusion polypeptides are capable of suppressing immunoresponsiveness of an immune cell, inhibiting production of proinflammatory cytokines, including inhibiting immune complex-induced production of cytokines.
Type:
Application
Filed:
January 14, 2010
Publication date:
September 23, 2010
Applicant:
VIRAL LOGIC SYSTEMS TECHNOLOGY CORP.
Inventors:
Craig A. Smith, Steven Wiley, Ajamete Kaykas, Peter Probst
Abstract: Provide herein are fusion polypeptides that comprise a CD47 extracellular domain or a variant thereof that is fused to a Fc polypeptide. The fusion polypeptides are useful for treating an immunological disease or disorder in a subject according to the methods described herein. The fusion polypeptides are capable of suppressing immunoresponsiveness of an immune cell, inhibiting production of proinflammatory cytokines, including inhibiting immune complex-induced production of cytokines.
Type:
Application
Filed:
May 15, 2007
Publication date:
June 5, 2008
Applicant:
Viral Logic Systems Technology Corp.
Inventors:
Craig A. Smith, Steven Wiley, Ajamete Kaykas, Peter Probst
Abstract: The present invention provides methods for identifying viral virulence factors and for identifying cellular polypeptides to which the viral polypeptides bind. The cellular polypeptide is useful as a therapeutic target or as a therapeutic agent for treating diseases and disorders, including immunological diseases or disorders.
Type:
Application
Filed:
March 22, 2007
Publication date:
November 15, 2007
Applicant:
Viral Logic Systems Technology Corp.
Inventors:
Steven Wiley, Craig Smith, Ajamete Kaykas
Abstract: The poxvirus proteins designated A41L and 130L bind to three receptor-like protein tyrosine phosphatases (RPTP), leukocyte common antigen related protein (LAR), RPTP-?, and RPTP-?, that are present on the cell surface of immune cells. When a host is infected with the poxvirus, binding of A41L to cell surface proteins on the host cells results in suppression of the immune response. The present invention provides agents such as antibodies, and antigen-binding fragments thereof, small molecules, aptamers, small interfering RNAs, and peptide-IgFc fusion polypeptides that interact with one or more of LAR, RPTP-?, and RPTP-? expressed by immune cells or interact with a polynucleotide encoding the RPTP. Also provided are RPTP Ig domain oligomers and Fc fusion polypeptides. Such agents are useful for treating an immunological disorder in a subject according to the methods described herein.
Type:
Application
Filed:
September 29, 2006
Publication date:
June 14, 2007
Applicant:
Viral Logic Systems Technology Corp.
Inventors:
Craig Smith, Steven Wiley, Ajamete Kaykas, Jalal Vakili, Peter Probst